Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group

Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group

CoronaVac vaccine from Sinovac Life Science is currently being used in several countries. In Chile, the effectiveness of preventing hospitalization is higher than 80% with a vaccination schedule. However, to date, there are no data about immune response induction or specific memory. For this reason,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Escobar, Alejandro, Reyes-López, Felipe E, Acevedo, Mónica L, Alonso-Palomares, Luis, Valiente-Echeverría, Fernando, Soto-Rifo, Ricardo, Portillo, Hugo, Gatica, Jimena, Flores, Ivan, Nova-Lamperti, Estefanía, Barrera-Avalos, Carlos, Bono, María Rosa, Vargas, Leonardo, Simon, Valeska, Leiva-Salcedo, Elias, Vial, Cecilia, Hormazabal, Juan, Cortes, Lina Jimena, Valdés, Daniel, Sandino, Ana María, Imarai, Mónica, Acuña-Castillo, Claudio
Format: Artikel
Sprache:eng
Schlagworte:
CoronaVac
COVID-19
Herd immunity
Immunological memory
Neutralizing antibodies
SARS-CoV-2
Vaccine
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:CoronaVac vaccine from Sinovac Life Science is currently being used in several countries. In Chile, the effectiveness of preventing hospitalization is higher than 80% with a vaccination schedule. However, to date, there are no data about immune response induction or specific memory. For this reason, we recruited 15 volunteers without previous suspected/diagnosed COVID-19 and with negative PCR over time to evaluate the immune response to CoronaVac 28 and 90 days after the second immunization (dpi). The CoronaVac administration induces total and neutralizing anti-spike antibodies in all vaccinated volunteers at 28 and 90 dpi. Furthermore, using ELISpot analysis to assay cellular immune responses against SARS-CoV-2 spike protein, we found an increase in IFN-gamma- and Granzyme B-producing cells in vaccinated volunteers at 28 and 90 dpi. Together, our results indicate that CoronaVac induces a robust humoral immune response and cellular immune memory of at least 90 dpi.